Diagnose
Building useful clinical tools to identify patients and boost their access to better treatment options.
With the digitization of pathology and the potential of machine learning, the wealth of information contained in pathology slides can be leveraged like never before.
Challenges
What if we could help clinicians deliver precision medicine to their patients?
Owkin is working to deliver AI diagnostics that integrate seamlessly into the digital pathology workflow to support accurate diagnosis at a fraction of the time and cost of existing tests. Our solutions help pre-screen for biomarkers and predict outcomes— giving healthcare providers a fuller picture of a patient’s disease. This means more patients can benefit from targeted therapies, making precision medicine more accessible to more patients at an earlier stage of their disease.
Treatment burden
Treatments for cancer can be toxic, invasive and expensive and may not always be necessary or effective
Disease heterogeneity
Cancer is a highly heterogeneous disease, even cancer of one tissue will have many subtypes that each respond to treatments differently
Anatomic pathology is underutilized
Digital Pathology slides hold vast amounts of hidden insights and unlike genomic data, they are routinely generated in the clinical workflow
Treatment burden
Treatments for cancer can be toxic, invasive and expensive and may not always be necessary or effective
Disease heterogeneity
Cancer is a highly heterogeneous disease, even cancer of one tissue will have many subtypes that each respond to treatments differently
Anatomic pathology is underutilized
Digital Pathology slides hold vast amounts of hidden insights and unlike genomic data, they are routinely generated in the clinical workflow
Owkin is working to deliver AI diagnostics that integrate seamlessly into the digital pathology workflow to support accurate diagnosis at a fraction of the time and cost of existing tests. Our solutions help pre-screen for biomarkers and predict outcomes— giving healthcare providers a fuller picture of a patient’s disease. This means more patients can benefit from targeted therapies, making precision medicine more accessible to more patients at an earlier stage of their disease.
Case study
82% sensitivity
70% specificity
Hazard Ratio of 5.25 between high and low risk groups
Testimonials
01/01
“Thanks to the solution we now have a better understanding of the underlying mechanism of highly aggressive tumors and the treatment needs for these patients. Identifying very high-risk patients earlier will enable us to adjust the therapeutic strategy for more favorable patient outcomes.”
Impact
Impact
Impact pathologists and clinicians
Oncologists can accelerate the clinical utility of specific treatments and give the patients the best possible care pathway.
Biopharma
Pharma can increase the statistical power of phase 3 trials by using this tool to select high-value subgroups with the greatest unmet need and that are most likely to benefit from the treatment.
Take a closer look
